What does STRATA Skin Sciences do and what are its main business segments?

What guidance did STRATA Skin Sciences's management provide for the next earnings period?

What is the revenue and EPS growth rate for STRATA Skin Sciences year over year?

What factors drove the changes in STRATA Skin Sciences's revenue and profit?

What is STRATA Skin Sciences's latest dividend and current dividend yield?

What is STRATA Skin Sciences's gross profit margin?

What were the key takeaways from STRATA Skin Sciences's earnings call?

What were the key takeaways from STRATA Skin Sciences’s earnings call?

- **CPT Code Expansion**: 30 new conditions expand addressable market to 30M+ patients, effective 2027.
- **Revenue Growth**: Recurring revenue +3% YoY, gross billings per device $5,981 (+8.5% YoY).
- **Litigation Recovery**: $1M in regained revenue from 24 clinics, potential for 75-100+ additional recoveries.
- **Mexico Expansion**: TheraClearX first commercial placement, targeting 3,000+ dermatologists in Q4 2025.
- **Financial Resilience**: Gross margin stable at 60%, operating expenses down 21% YoY.

**【CEO Summary Section】**
- Expanded CPT codes for XTRAC excimer laser treatments to include 30 new conditions (e.g., vitiligo, atopic dermatitis), tripling the addressable patient population to over 30 million, effective January 1, 2027.
- 99 partner clinics in the Elevate 360 program achieved 7% YoY revenue growth, with average gross billings per device at $5,981 (8.5% YoY increase).
- Recovered $1M in recurring revenue from 24 clinics misled by competitor's false claims about PALLAS solid-state lasers.
- TheraClearX received regulatory approval in Mexico, with first commercial placement and plans for U.S.-style revenue-sharing agreements.

**【CFO Financial Commentary】**
- Q3 2025 total revenue: $6.9 million (-20% YoY), driven by international trade policy challenges.
- Recurring revenue: $5.5 million (+3% YoY); equipment revenue: $1.4 million (-60% YoY).
- Gross profit: $4.2 million (60% margin, flat YoY); operating expenses: $5.4 million (-21% YoY).
- Net loss: $1.6 million (-24% YoY); cash: $7.1 million.

**【Q&A Highlights】**
- DTC campaign efficiency: 8.5% increase in gross billings per device, with better cost per acquisition and show rates.
- Mexico strategy: TheraClearX registered with COFEPRIS, targeting 3,000+ dermatologists for placements in Q4 2025.
- Litigation: 2 dozen clinics returned to XTRAC, with potential for additional recoveries from 75-100 accounts misled by competitor.
- CPT code timeline: Expanded codes finalized for 2027, no temporary codes for 2026 to avoid market confusion.

STRATA Skin Sciences, Inc. (SSKN) Q3 2025 Earnings Call Transcript

- **Market Expansion**: CPT code expansion triples TAM to 30M patients, with potential 2026 G code acceleration.
- **Litigation Strength**: $10M+ damages claimed against LaserOptek for false advertising; new defendants added to ensure recovery.
- **Revenue Challenges**: Q2 2025 revenue down 9% YoY to $7.7M, driven by 15% international decline and U.S. device underutilization.
- **Legal Costs**: Q2 legal expenses: $340K; total lawsuit-related costs expected to exceed $1M in 2025.
- **Key Growth Driver**: 19 new U.S. placements in Q2 (highest in 6 quarters), signaling renewed partner confidence.

**【CEO Summary Section】**
- Expanded CPT codes for XTRAC 308-nm excimer laser now cover 30+ indications, including vitiligo, atopic dermatitis, and CTCL, tripling the total addressable market (TAM) to 30 million patients.
- Temporary G codes could accelerate revenue by 1 year, with potential reimbursement rate increases based on submitted economic data.
- Installed base optimization: Removed 21 underperforming devices, added 19 new placements (highest in 6 quarters), ending Q2 with 844 units in the U.S.
- DTC campaigns generated 1,100 appointments (61% show rate) and RDX system handled 5,100 patients, including 2,500 psoriasis and 1,000 acne cases.
- Litigation against LaserOptek for false advertising claims damages in the $10+ million range; new defendants added to ensure recovery.
- Q2 international revenue declined 15% YoY to $2.6M due to China trade disruptions, but strong underlying demand in Asia-Pacific markets.

**【CFO Financial Commentary】**
- Total Q2 2025 revenue: $7.7M (-9% YoY), with U.S. recurring billings at $4.7M (-2% YoY) and equipment revenue at $2.5M (-18% YoY).
- Gross profit: $4.3M (56% of revenue), down from $5.0M YoY due to lower sales and higher manufacturing costs.
- Operating expenses: $6.5M (+$1M YoY), driven by +16% selling/marketing and +$340K legal costs for the LaserOptek lawsuit.
- Adjusted EBITDA loss: $762K; cash balance: $6M.

**【Q&A Key Highlights】**
- **International Business Outlook**: Q2 2025 international revenue down 15% YoY; 2025H2 expected to mirror 2024H2 trends, but tariffs remain a risk.
- **Lawsuit Costs**: Q2 legal expenses: $340K; total expected damages: $8-10M; discovery phase nearing completion.
- **Temporary G Codes Timeline**: CMS 2026 final rule expected in November 2025; potential 2026 implementation with higher reimbursement rates.
- **Elevate 360 Impact**: 100+ clinics optimized; one Florida clinic increased patient utilization from 6% to 25% after program implementation.
- **TheraClearX Growth**: Installed base: 161 units (vs. 117 in Q2 2024); focus on XTRAC as primary growth driver.

STRATA Skin Sciences, Inc. (SSKN) Q2 2025 Earnings Call Transcript

- **Revenue Resilience**: Q1 2025 recurring revenue growth streak continues at 4 quarters YoY, with XTRAC utilization gains.
- **Strategic Breakthrough**: Elevate 360 program expanded to 100 accounts, driving $15M+ incremental revenue potential.
- **TheraClearX Surge**: 160 devices deployed, 1,000 patients processed Q1, 138% YoY growth in reimbursement volume.
- **Profitability Boost**: Gross margin 53.5%, best Q1 EBITDA since 2022, with operating expenses down 5% YoY.
- **Tariff Risk**: 145% tariffs threaten 50%+ international revenue decline if unresolved, impacting warranty parts supply chains.
- **Cash Position**: $7.8M cash (including $1.3M restricted), improving cash burn to $749K Q1 (vs. $1.55M prior year).


**【Management Opening Remarks】**
- STRATA Skin Sciences released Q1 2025 financial results, highlighting execution of its turnaround strategy.
- CEO Dolev Rafaeli emphasized focus on optimizing device utilization, Direct-to-Consumer (DTC) marketing, and international expansion despite tariff risks.

**【CEO Commentary】**
- **Revenue Growth**: Q1 2025 marks the fourth consecutive quarter of year-over-year growth in average net recurring revenue per XTRAC device in the US.
- **Strategy Execution**: Elevate 360 consulting program expanded to 100 accounts, driving device utilization and revenue. For example, one partner clinic increased revenue from $13,000 to $28,000 QoQ through program implementation.
- **TheraClearX Momentum**: Installed base grew to 160 devices (vs. 104 in Q1 2024), with 1,000 patients processed through reimbursement support (up 138% YoY).
- **Tariff Risk**: Warning that unresolved tariffs could reduce international revenue by 50%+ in future quarters.

**【CFO Financial Commentary】**
- **Revenue**: Total Q1 2025 revenue $6.8M (flat YoY), with recurring revenue $4.7M (up 1% YoY).
- **Profitability**: Gross margin improved to 53.5% (vs. 45.6% Q1 2024), driven by recurring revenue efficiency. Non-GAAP EBITDA $732K (best since Q1 2022).
- **Cost Control**: Operating expenses down 5% YoY to $5.7M, with engineering costs reduced 60%.
- **Cash Flow**: Cash burn $749K (vs. $1.55M Q1 2024), ending with $7.8M cash (including $1.3M restricted for tax audit).

**【Q&A Highlights】**
- **TheraClearX Pipeline**: Full deployment of 250 owned devices expected by Q1 2026. Each patient generates $300+ in revenue, with 1,000 Q1 patients translating to $1.8M annualized revenue.
- **Utilization Trends**: XTRAC breakeven at $18K/device/year, TheraClearX at $9K/device/year. Q1 2025 saw 6,000 TheraClearX procedures (24,000 annualized).
- **Tariff Impact**: 145% tariffs on Asian imports could disrupt warranty parts supply chains, potentially halting international sales growth.
- **Installed Base Strategy**: Focus on redeploying 100+ idle devices into high-potential clinics via Elevate 360, with 7 new deployments in Q1 2025.


STRATA Skin Sciences, Inc. (SSKN) Q1 2025 Earnings Call Transcript

- **Revenue Growth**: Q4 2024 total revenue up 10% YoY to $9.6M, driven by international sales ($4.1M, +41% YoY) and improved U.S. device utilization.
- **Profitability Boost**: Gross margin expands to 60.1% (vs. 55.3% YoY), operating loss down 68% YoY.
- **TheraClearX Momentum**: 144 devices installed, 108 now billing insurance, with >3,700 patient preauthorizations.
- **Strategic Focus**: Removing underperforming accounts (10% annual churn), prioritizing high-volume clinics with >1,000 relevant patients.

**【CEO Opening Remarks】**
- **Revenue Performance**: Q4 2024 total revenue $9.6M, up 10% YoY. U.S. XTRAC installed base declined to 864 units but average gross billing per device rose 5% YoY to $5,637, driven by strategic focus on high-performing clinics.
- **Gross Margin Improvement**: Q4 gross margin 60.1%, up 480bps YoY, nearing 2019-2021 peak levels of ~70%.
- **International Growth**: International sales $4.1M (27% QoQ, 41% YoY), led by Japan with ~100 XTRAC devices sold since 2019.
- **TheraClearX Expansion**: 144 devices installed (up from 92 in 2023), with 108 now billing insurance and >3,700 patient preauthorizations secured.

**【CFO Financial Details】**
- **Revenue Breakdown**: Q4 2024 total revenue $9.6M (10% YoY growth). Equipment revenue $3.8M (29% YoY), driven by international sales. Recurring billings $4.87M (down 1.5% YoY).
- **Profitability**: Gross profit $5.8M (12% YoY), operating loss improved 68% YoY (adjusted for non-cash charges). Cash balance $8.6M, supporting 2025 growth initiatives.
- **Cost Management**: Normalized operating expenses $6.1M (flat YoY), reflecting disciplined expense control.

**【Q&A Highlights】**
- **TheraClearX Adoption**: Northeast clinics leading with 1-2 device pilots, achieving 86% patient preauthorization rates. Expanding to private equity-backed groups with >15 devices.
- **International Drivers**: Japan's high patient volume (devices used 20-50x more frequently than U.S.), China's public-private hospital adoption, and Middle East's shift from public tenders to private clinics.
- **Account Management Strategy**: Removing ~10% underperforming accounts annually, replacing with high-potential clinics (e.g., 1,000+ relevant patients per office).

SSKN

SSKN fundamentals

Earnings Call

You can ask Aime